Article

ALK/ATR combination therapy is effective in neuroblastoma mouse tumors driven by MYCN

2025-07-21

Abstract excerpt

<h4>Summary paragraph</h4> One of the key features of high-risk neuroblastoma (NB) is MYCN -amplification. While MYCN is still regarded as therapeutically challenging despite intensive efforts to find targeting compounds, inhibitors against Anaplastic Lymphoma Kinase (ALK) are now being evaluated among ALK-driven NB patients with promising results. There is a pressing need to find alternative treatment regimens...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b82ec0c1-75fe-5615-9790-085457302b30
DOI: 10.1101/2025.07.17.665300

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ALK/ATR combination therapy is effective in neuroblastoma mouse tumors driven by MYCNDOI 10.1101/2025.07.17.665300Read

ALK signalling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibitionSemantic proximity Read

ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibitionSemantic proximity Read

ATR inhibition enables complete tumour regression in ALK-driven NB mouse modelsSemantic proximity Read

<i>MYCN</i> Amplification and <i>ATRX</i> Mutations are Incompatible in NeuroblastomaSemantic proximity Read

MYCN amplification and ATRX mutations are incompatible in neuroblastoma.Semantic proximity Read

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELSSemantic proximity Read

Neuroblastoma models for insights into tumorigenesis and new therapies.Semantic proximity Read

DNA Damage Response Deficiency Enhances Neuroblastoma Progression and Sensitivity to Combination PARP and ATR InhibitionSemantic proximity Read

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatmentSemantic proximity Read

RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastomaSemantic proximity Read

Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH‐MYCN neuroblastoma mouse modelSemantic proximity Read

DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibitionSemantic proximity Read